Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 659-664

  Shitara, K ^a   Ito, S ^a   Misawa, K ^a   Ito, Y ^a   Ito, H ^a   Hosono, S ^a   Watanabe, M ^a   Tajima, K ^a   Tanaka, H ^a,b   Muro, K ^a   Matsuo, K ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastrectomy; Gastric cancer; Genetic polymorphism; IGF I; Recurrence

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; SOMATOMEDIN C;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GASTRECTOMY; GENDER; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

EID: 84857558997     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr293     Document Type: Article

References (23)

1. International Agency for Research on Cancer. GLOBOCAN 2008. http://wwwdep.iarc.fr/CancerMondial.htm (25 November 2010, date last accessed).
2. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
3. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New Engl J Med 2007; 357: 1810-1820.
4. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Paoletti X, Oba K et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737.
5. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer. NCCN Practice Guidelines in Oncology, version 2. 2010.; http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (15 June 2011, date last accessed).
6. Wagner AD, Grothe W, Haerting J et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
7. Samani AA, Yakar S, LeRoith D et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
8. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
9. Zhang M, Hu Z, Huang J et al. A 3'-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res 2010; 16: 1236-1244.
10. Tsuchiya N, Wang L, Suzuki H et al. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 2006; 24: 1982-1989.
11. Dong X, Javle M, Hess KR et al. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 2010; 139: 464-473.
12. Tajima K, Hirose K, Inoue M et al. A model of practical cancer prevention for outpatients visiting a hospital: the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Asian Pac J Cancer Prev 2000; 1: 35-47.
13. Hamajima N, Matsuo K, Saito T et al. Gene-environment interactions and polymorphism studies of cancer risk in the Hospital-based Epidemiologic Research Program at Aichi Cancer Center II (HERPACCII). Asian Pac J Cancer Prev 2001; 2: 99-107.
14. International HapMap Consortium. The international HapMap project. Nature 2003; 426: 789-796.
15. Thorisson GA, Smith AV, Krishnan L, Stein LD. The international HapMap project web site. Genome Res 2005; 15: 1592-1593.
16. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999; 14: 143-149.
17. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer 1998; 1: 10-24.
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
19. Al-Zahrani A, Sandhu MS, Luben RN et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006; 15: 1-10.
20. Johansson M, McKay JD, Wiklund F et al. Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. J Clin Endocrinol Metab 2007; 92: 4820-4826.
21. Deming SL, Ren Z, Cai Q et al. IGF-I and IGF-II genetic variation and breast cancer risk in Chinese women: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2008; 17: 255-257.
22. Patel AV, Cheng I, Canzian F et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 2008; 3: e2578.
23. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010; 16: 2512-2517.